PDP1 and familial pancreatic carcinoma: Huang et al. demonstrated that PDP can mitigate drug delivery barriers in the TME to safely widen the therapeutic window of FDA-approved nanoliposomal irinotecan (nal-IRI) in a preclinical model of pancreatic cancer [42].